Session date: 
07/26/2024 - 12:00pm to 1:00pm

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify commonly used cancer treatments with cardiovascular toxicity
  • Recognize limitations to our current clinical and mechanistic understanding of anthracycline cardiotoxicity
  • Recall how basic and translational research approaches can inform risk stratification and prevention of cardiovascular toxicity in patients treated for cancer

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

"Credit (if available) is announced on the Group Home page. All sessions are reviewed individually, and credit is pulled for any that does not meet the criteria." 

Presenter: 
Aarti Asnani, MD
Where did the idea for the course originate?: 
Florida
Please login or register to take this course.
Where did the idea for the course originate?: 
Florida